Metabolism-Mediated Thrombotic Microangiopathy in an Older ...

royal bleeding disease :: Article Creator

Hemophilia: Breakthrough Therapies Aim To 'dethrone' The Disease Of Kings

A London wedding on February 10, 1840, put hemophilia center stage of an international political drama. Queen Victoria of England married Prince Albert of Saxe-Coburg-Gotha and unwittingly passed on a defective gene to their children that causes a disease that impairs the body's ability to control bleeding. The couple's nine children married and spread hemophilia throughout other European monarchies. Despite their royal power, these nobles could do little to combat incapacitating hemorrhages and premature deaths.

Almost two centuries later, in a town near A Coruña (Spain), a security system operator has become one of the first hemophiliacs in the world to experience something for which many monarchs would have given up a crown: a gene therapy that produced complete remission of hemophilia symptoms for more than three years. "It has been a mind-blowing process," said Iván Torcal.

Torcal remembers the constant fear of his childhood. "I have severe hemophilia. Not only do I hemorrhage from minor bumps and cuts, but they also occur spontaneously in my joints – elbows, knees, ankles... They swell and hurt, and I lose mobility. I have to lead a very careful and planned-out life. I go several times a week to the hospital to get my clotting factor treatment. This is a difficult way to live when you are older – imagine what it's like for a child. Your parents are on top of you all day long," he said.

In August 2019, Torcal went to his local public health system hospital (Complejo Hospitalario Universitario de La Coruña) to enroll in a clinical trial. They gave him an intravenous injection of a laboratory-modified virus that transports to the liver a healthy gene with the clotting factors that hemophiliacs lack.

"It was all quite slow and calm," said Torcal. "They monitored me for a few hours and sent me home once they saw I was fine." When he woke up the next day, Torcal really was okay. Tests immediately showed very high levels of clotting factors – his liver had started to produce them, just like people without hemophilia. "After a lifetime of being constantly careful, everything changes. You don't get hurt from a little bump, you can ride a bike without worrying, and your joints no longer hurt. At first, it's all very strange," he said.

Torcal suffers from hemophilia A, caused by a congenital deficiency of clotting factor VIII. Almost half of the patients suffering from this type of hemophilia develop a serious or severe form of the disease. Depending on the clotting factor levels in the blood, others will develop moderate or mild forms of the disease and don't bleed or hemorrhage as easily. According to Spain's Ministry of Public Health, hemophilia A occurs in six of every 100,000 people in the European Union.

Hemophilia B, caused by a deficit in clotting factor IX, is rarer and causes similar disorders. Spain's Ministry of Public Health reports that 77 people in the country have been genotyped with severe hemophilia B and 50 with the moderate form. However, the total number of affected people could be around 300. Hemophilia C – the third type of the disease – is less prevalent and generally much milder.

Victor Jiménez Yuste, vice-president of the Spanish Society of Hematology and Hemotherapy (SEHH) and a hematology specialist at La Paz Hospital in Madrid, says hemophilia almost always affects men rather than women. "The gene responsible for hemophilia A and B is on the X chromosome," said Jiménez. "Women can be carriers since they have two X chromosomes, but won't develop the disease because they still have one healthy gene. But a female carrier has a 50% chance of passing on the affected chromosome to her children. Since men only have one X chromosome [the other is Y], they will certainly be hemophiliacs if they inherit the gene."

Dr. Jiménez describes the new gene therapy as a "real revolution. We made more progress in the last few years than in the previous three or four decades. Before, we only had factor VIII or IX replacement treatments with blood derivatives obtained from donors. Then recombinant drugs emerged." These drugs are synthesized in a laboratory and offer much better patient safety. The blood derivatives used in the past frequently contained viral infections that were passed on to hemophilia patients when injected. Spain's Hemophilia Federation estimates that 1,000 hemophiliacs died in Spain from HIV and hepatitis C in the last two decades of the 20th century.

Gradual medical advances enabled hemophiliacs to approach the life expectancy of the rest of the population. But their quality of life still suffered. "Patients must go to the hospital several times a week for these intravenous prophylactic drugs," said Jiménez. People with mild cases can lead more or less normal lives since they only need the clotting factor when they have a wound." Some patients also develop antibodies to the clotting factor when it's identified as foreign by their bodies, which worsens the prognosis and complicates treatment.

The approval of Hemlibra (Roche) by Spain's public health system in 2019 represented a significant qualitative benefit for patients with hemophilia A. Depending on the case, this treatment can be administered with a simple subcutaneous prick weekly, biweekly or monthly. "Gene therapies are the great leap forward we needed," said Jiménez.

While it was still in clinical trials, Iván Torcal received Roctavian (BioMarin), the first gene therapy approved by the European Medicines Agency (EMA). The drug was authorized for sale by the European Commission for hemophilia A in August 2022. In February 2023, the Commission approved Hemgenix (CSL Behring) for hemophilia B.

Vicente Arocas, a Spanish Society of Hospital Pharmacy (SEFH) drug evaluation group member, said, "These treatments have very high initial efficacy and can elevate factors VIII and IX a great deal, depending on the case. But after six months, the levels start dropping, and we don't know how long they will be effective. That's why the EMA has only granted them conditional approval until the pharmaceutical companies provide more data."

The other big question is patient safety. "The trials and real-life data include very few patients, so we still don't know the less frequent side effects," said Arocas. "We do know that they have liver toxicity and that the DNA used can be introduced into other cells in the body, which carries the risk of patients developing some types of cancer."

Iván Torcal told us that despite the promising results he experienced, he also developed "elevated liver transaminase levels," forcing him to take corticoids for about 18 months. Transaminases are important in the synthesis of amino acids, which form proteins. "I gained about 10 or 12 kilos with the treatment, which was quite annoying," said Torcal. Disappointingly, his coagulation factor levels have dropped significantly after three and a half years of Roctavian treatments. He may soon have to return to the old treatments before the gene therapy.

Fernanda López is the head of hematology at the hospital where Torcal was treated. "The coagulation factor levels of the four patients we have treated here dropped greatly since the first year. But they only have mild hemophilia and can lead almost normal lives. In Iván's case, I'd say he's back to moderate hemophilia."

Despite the "gigantic progress" offered by the first gene therapies, López believes there is still potential for improvement. "They can't be used to treat children right now, nor for liver patients or people with antibodies to the virus used as a vector."

A dozen other gene therapies are being developed to treat hemophilia A and B and offer the potential of a complete cure or long-term remission. The available data suggest a symptom remission duration of up to 10 years in hemophilia A and 20 years in hemophilia B. However, clinical trial projections often have to be lowered when treatments are approved for use in the real world.

In Spain, treatment coverage by the public health system is still being negotiated as the companies that developed Roctavian (BioMarin) and Hemgenix (CSL Behring) are asking for exorbitant prices. In other countries, Roctavian costs close to $1.6 million (€1.5 million), and Hemgenix costs $3.5 (€3.3 million), making it the most expensive drug in the world.

"These are very innovative treatments and therefore require innovative financing systems," said FEDHEMO president Daniel-Aníbal García Diego. "One financing method used for other innovative drugs is outcome-based payment. Public health systems pay annually until the treatment ceases to be effective. Remember that the average cost of current hemophilia treatments is nearly $215,000 (€200,000). But an excellent product is useless if healthcare systems can't afford it."

Bleeding Disorder Awareness Month: Types Of Bleeding Disorders And Their Treatment

Hemophilia, commonly referred to as the "royal sickness" is a hereditary condition that can cause uncontrollable bleeding in the patient. This occurs as a result of their blood's deficiency in a component that aids in clotting. If left untreated, it can be fatal.The following are the most prevalent bleeding disorders out of the many diverse types that are there:● Haemophilia A and Haemophilia B - Low levels of clotting factors in your blood can cause the disorders haemophilia A and haemophilia B. It results in significant or uncommon joint haemorrhage. Although haemophilia is uncommon, its complications can be fatal.● Factor II, V, VII, X, or XII - Blood clotting or abnormal bleeding issues are linked to bleeding diseases caused by factor II, V, VII, X, or XII deficits.

● Von Willebrand's disease - This inherited bleeding condition is the most common. It occurs when the blood is deficient in the von Willebrand factor, which aids with blood clotting.

Symptoms Bleeding problems can present with symptoms like:

● Heavy bleeding from minor incisions or dental work● Easy bruising● Excessive and unexpected nosebleeds● Bleeding gums● Joints start to bleed● Extreme menstrual bleeding● Bleeding excessively after surgery

Treatment Depending on the type of disorder, different therapies, including medication and factor replacement therapy, may be used to treat bleeding disorders.

When you have an accident or plan to have surgery, you may need to receive treatment on a need-to-know basis or daily to avoid bleeding episodes.

Medications Among the medications used to address bleeding disorders are: AntifibrinolyticsDesmopressin (DDAVP) - a hormone produced by humans, Immune-suppressing drugs, and vitamin K supplements. Factor Replacement Therapy Using clotting factors created in a lab or obtained from blood donors, factor replacement therapy replaces the missing clotting factor.Factor replacement treatment might consist of: ● Bypassing medicines ● Fresh frozen plasma ● Clotting factor concentrates If you are also suffering from this genetic disorder, then going through counselling is a great idea to prevent the disease. Dr. Lalit Raut, Hematologist & Stem Transplant Physician, MD-Medicine, Lybrate

'It Broke My Heart Seeing The Fear In Their Eyes': Woman Shares Story Of AML Diagnosis

A former teaching assistant lost her Dad to acute myeloid leukaemia (AML) when she was just 17 and years later she was diagnosed with the same illness.

Ahead of World AML Day on April 21, Sharon Sinclair, 58, from Wildmore, Bromley South, is sharing her story of being diagnosed with AML.

Mrs Sinclair said: "I thought I knew the signs of blood cancer, my Dad died of AML when I was 17.

"He went in for blood tests on the Monday, went into Royal Marsden on the Tuesday, and died the next day while I was waiting to go and see him.'

Mrs Sinclair's Dad, Patrick Sinclair, was just 41 at the time.

In October 2018 Mrs Sinclair was experiencing fatigue and breathlessness.

On January 3, 2019, Mrs Sinclair's GP fast tracked her to Princess Royal Hospital in Farnborough.

Mrs Sinclair said: "I had a bone marrow test done and within 2 hours was told I had acute myeloid leukaemia. It was a huge shock."

AML is a type of blood cancer which can affect anyone of any age. The disease claims over 2,600 lives each year in the UK and has a 5-year survival rate of just 15.3 per cent.

The disease progresses very quickly, and usually requires immediate treatment. Common symptoms include fatigue, bruising or bleeding, and repeated infections.

Mrs Sinclair, who was 54 when she was diagnosed, began chemotherapy immediately but was only given a 40 per cent chance of success.

She said: "My poor Mum was beside herself, having to tell my husband John, who I've been married to for 33 years, and my two sons Johnny and Luke, was awful.

"It broke my heart seeing the fear in their eyes."

Mrs Sinclair went into remission after her first round of chemotherapy but still needed a bone marrow transplant to improve her chances.

A match was found in Germany and, after another round of chemo, Mrs Sinclair went to King's College Hospital in London for a stem cell transplant. In December 2019, Mrs Sinclair was told she was 100 per cent clear from cancer.

The charity Leukaemia UK is calling on the public to help fund more research, which is desperately needed to stop the disease devastating lives in future.

For more information visit: http://www.Leukaemiauk.Org.Uk/

Pictured Top: Sharon Sinclair, before, during and after AML (Picture: Leukaemia UK)

Or, please make cheques payable to "MSI Media Limited" and send by post to South London Press, Unit 112, 160 Bromley Road, Catford, London SE6 2NZ

Former Housing Secretary Robert Jenrick has encouraged everyone in the country who can afford to do so to buy a newspaper, and told the Downing Street press briefing: "A free country needs a free press, and the newspapers of our country are under significant financial pressure".

So if you have enjoyed reading this story, and if you can afford to do so, we would be so grateful if you can buy our newspaper or make a donation, which will allow us to continue to bring stories like this one to you both in print and online.

Everyone at the South London Press thanks you for your continued support.

Search This Blog

Congenital Hearing Loss